LKFT - Lakefront Biotherapeutics N.V.
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
As of Aug 14, 2026: spot at $27.53, ATM IV 63.2%, net GEX $2.8K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $1.84B
- P/E Ratio
- 3.27
- Beta
- 0.12
- 52-Week Range
- 25.68-37.78
- CEO
- Henry O. Gosebruch
- Employees
- 452
- IPO Date
- May 5, 2005
- Exchange
- NASDAQ
What LKFT Looks Like to Options Traders Today
positive net gamma exposure ($2.8K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.130) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The LKFT overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked LKFT overview questions
- What is LKFT?
- LKFT is the ticker symbol for Lakefront Biotherapeutics N.V., a listed security. Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. Listed on NASDAQ. LKFT is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the LKFT options snapshot look like today?
- As of Aug 14, 2026, the LKFT options snapshot shows spot at $27.53, ATM IV 63.2%, net GEX $2.8K, expected move 18.12%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are LKFT's key statistics?
- Lakefront Biotherapeutics N.V. (LKFT) carries a market capitalization of $1.84B, trailing P/E ratio of 3.27, beta of 0.12 relative to the broader market, 52-week range of 25.68-37.78. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does LKFT belong to?
- Lakefront Biotherapeutics N.V. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LKFT's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the LKFT data on this page?
- The options snapshot above is dated Aug 14, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).